莫沙必利对氯氮平所致低结肠动力的临床疗效研究  

Study on the clinical efficacy of mosapride on clozapine-induced low colon motility

作　　者：徐鸥[1] 董介正[1] 邱龄山[1] 孙晓花[1] 

机构地区：[1]杭州市第七人民医院精神科,浙江杭州310013

出　　处：《中国现代医生》2016年第31期87-90,共4页China Modern Doctor

基　　金：浙江省医药卫生科技计划一般项目(2015KYB303);杭州市卫生计生科技计划一般项目(2016A48)

摘　　要：目的研究莫沙必利对氯氮平所致低结肠动力的影响,观察其治疗慢传输型便秘的临床疗效。方法选取服用氯氮平的结肠试验异常者106例,分为治疗组、对照组,各53例,分别予肠动力药莫沙必利及传统泻药酚酞片治疗;疗程30 d。观察治疗前后的72 h结肠传输试验、疗程结束后两组症状积分,统计药物不良反应,并随访6个月,比较复发情况。结果 1个月后两组便秘症状积分均有下降(P<0.01),治疗组减分更为明显(P<0.05)。6个月后两组症状积分较1个月相比均上升(P<0.05)。1个月后治疗组72 h钡剂标志物排出情况正常例数明显优于对照组(P<0.01)。6个月后,治疗组72 h钡剂标志物排出情况仍优于对照组(P<0.05)。1个月后对照组腹泻人次明显多于治疗组(P<0.01)。6个月与1个月相比,两组复发人数逐渐增多、开塞露使用情况增加(P<0.05);对照组发生腹泻人次较第1个月明显减少(P<0.01)。结论莫沙必利能有效改善结肠动力,是治疗氯氮平所致慢传输型便秘安全有效的药物,可作为临床新的用药选择,缺陷是停药后复发率比较高。Objective To study the effect of mosapride on low colon motility induced by clozapine, and to observe its clinical efficacy on slow transit constipation. Methods 106 patients with abnormal colonic test were selected and divided into treatment group and control group, with 53 patients in each group. They were given prokinetic drug of mosapride and traditional drug of phenololphthalein tablets; the treatment course was 30 days. 72-hour colonic transit test was observed before and after the treatment. After the end of treatment, the symptomatic score was calculated in both groups. Adverse drug reactions were statistically analyzed, and the patients were followed up for six months. The recur- rence was compared. Results After 1 month, the score of constipation symptom was decreased in both groups （P〈0.01）, and the score was decreased more significant in the treatment group （P〈0.05）. The symptom scores of both groups were increased after 6 months compared with those after 1 month （P〈0.05）. 1 month after the treatment, the discharge of 72- hour barium markers was normal, significantly better than that in the control group （P〈0.01）. After 6 months, the dis- charge of 72-hour barium marker in the treatment group was still better than that in the control group （P〈0.05）. The number of patients with diarrhea in the control group was significantly more than that in the treatment group after 1 month （P〈0.01）. after six months, the number of recurrent cases was increased and the use of ketamine was increased in both groups compared with those after 1 month （P〈0.05）; the number of people with diarrhea was significantly lower in the control group than that in the first month（P〈0.01）. Conclusion Mosapride is able to effectively improve the colon motility and is one of the safe and effective drugs for the treatment of slow transit constipation induced by clozapine. It can be used as a choice of new clinical drug, but the defect is relatively high recurrence rate after drug withdrawal

关 键 词：莫沙必利 氯氮平 低结肠动力 慢传输型便秘 

分 类 号：R749.3[医药卫生—神经病学与精神病学]